Aligos Therapeutics (ALGS) Income from Continuing Operations (2019 - 2026)
Aligos Therapeutics (ALGS) reported Income from Continuing Operations of 23040000.0 for Q1 2026, down 153.47% on a YoY basis from 43088000.0 in Q1 2025, and down 15.89% quarter-over-quarter from 19881000.0 in Q4 2025.
Aligos Therapeutics (ALGS) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Aligos Therapeutics has reported Income from Continuing Operations for 8 years, with the latest figure at 23040000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 153.47% year-over-year to 23040000.0; the trailing twelve-month figure through Mar 2026 stood at 90321000.0 (down 69.59% YoY), and the FY2025 full-year result was 24193000.0, up 81.56% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 23040000.0, down from 19881000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 43088000.0 in Q1 2025, with the low at 82150000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 21304058.82 across 5 years, with a median of 19924000.0 in 2022.
- The largest YoY upside for Income from Continuing Operations was 223.59% in 2025 against a maximum downside of 413.44% in 2025.
- Aligos Therapeutics' Income from Continuing Operations stood at 21886000.0 in 2022, then retreated by 27.44% to 27892000.0 in 2023, then tumbled by 194.53% to 82150000.0 in 2024, then surged by 75.8% to 19881000.0 in 2025, then slipped by 15.89% to 23040000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 23040000.0 (Q1 2026), 19881000.0 (Q4 2025), and 31537000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Aligos Therapeutics | 51.70 Mn | -28.13 Mn | - | -23.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.04 Mn |
| Dec 31, 2025 | -19.88 Mn |
| Sep 30, 2025 | -31.54 Mn |
| Jun 30, 2025 | -15.86 Mn |
| Mar 31, 2025 | 43.09 Mn |
| Dec 31, 2024 | -82.15 Mn |
| Sep 30, 2024 | -19.26 Mn |
| Jun 30, 2024 | 5.06 Mn |
| Mar 31, 2024 | -34.86 Mn |
| Dec 31, 2023 | -27.89 Mn |
| Sep 30, 2023 | -18.04 Mn |
| Jun 30, 2023 | -18.79 Mn |
| Mar 31, 2023 | -22.96 Mn |
| Dec 31, 2022 | -21.89 Mn |
| Sep 30, 2022 | -18.62 Mn |
| Jun 30, 2022 | -19.92 Mn |
| Mar 31, 2022 | -35.62 Mn |
| Dec 31, 2021 | -37.71 Mn |
| Sep 30, 2021 | -33.12 Mn |
| Jun 30, 2021 | -29.82 Mn |